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There are various bioactive peptides in the skin secretions of amphibians, 
which play an essential role in amphibian survival in consideration of the 
complicated natural and artificial factors. It is proven that many of these 
peptides exhibit antimicrobial, anticancer, antiviral and trypsin inhibitory 
activities and therefore their potential promising therapeutic value has 
drawn great attention from numerous researchers 
In this study, a novel antimicrobial peptide was isolated and identified 
from the skin secretion of the frog, Phyllomedusa camba. A “shotgun” 
cloning technique was used to select the biosynthetic precursor sequence 
and a cDNA library was constructed for amplification of the target 
sequence. The peptide was isolated and identified using HPLC, 
MALDI-TOF mass spectrometry. 
The synthetic replicate exhibited a broad spectrum antimicrobial activity 
against Gram-positive bacteria Staphylococcus aureus, Gram-negative 
bacteria Escherichia coli and the yeast Candida albicans at 
concentrations of 4, 32 and 4 µM, respectively. The haemolysis of this 
peptide was not significant at low concentrations but had a considerable 
increase at high concentrations. The concentration of the test peptide 
which induced 50% haemolysis (HC50) was 23 μM. The results indicated 
that the discovered peptide can be potential drug candidates for the design 





















Amphibians which have evolved a wide range of morphological and ecological types 
are among the most fascinating and numerous of terrestrial vertebrates. They 
represent the transitional types of vertebrates from fully aquatic fishes to terrestrial 
amniotes. In the successful attainment of independence from water and colonisation 
of land, amphibians have undergone a remarkable adaptive radiation. Their skin 
which is exposed to the constantly-changing environment, helps them defend against 
the invasion by many microorganisms, parasites and even predators. From this view, 
the skin of amphibians provides useful information about promising functional 
molecules and has potential clinical applications. 
 
1.1 Factors affecting the living conditions of amphibians 
Since the first International Reptile Congress in 1989, the decline in amphibian 
populations has become a hot topic for many reptile zoologists. Especially in natural 
habitats such as national parks, nature reserves and some mountainous areas, the 
decline is obvious and has aroused widespread concern by reptile zoologists 
(Barinaga, 1990; Wyman, 1990). By 1993, more than 500 frogs and salamander 
species had been classified as declining and groups needed to be protected (Alford & 
Richards, 1999). The data provided by Amphibia Web (Web, 2009) showed that more 
than 200 amphibian species worldwide have experienced a recent decline in 
population, including 32 species extinctions, and most of these species have been 
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extinct in the past two to three decades. 
 
Amphibians are more sensitive to the environment and have higher requirements for 
external conditions than other land or water animals. Their growth state can be used 
as a measure of the quality of the global ecosystem and a natural indicator of the 
biological health of the Earth. In other words, as an important part of the ecosystem, 
the decline in the number of global amphibian species will have an important impact 
on other organisms (Blaustein, Wake and Sousa, 1994). 
 
Since there are rich resources in amphibians and we can take advantage of them for 
medical use, more attention should be paid to their living conditions. Generally, 
amphibians are vulnerable to a lot of other factors including pathogens (Blaustein et 
al., 1994), UV-B radiation (Häkkinen et al., 2001), pesticides (Baker et al., 2013), and 
exotic predators (Adams, 2000; Cruz et al., 2008).  
 
One of the main causes associated with the alarming decline and extinction crisis of 
amphibians worldwide is chytridiomycosis. The fungal pathogen Batrachochytrium 
dendrobatidis (Bd) bears most of the responsibility for this amphibian disease. 
Scheele reported that chytridiomycosis resulted in severe age structure truncation, 
which sequently increased vulnerability to other sources of mortality (Scheele, 2016).  
 
Besides that, habitat loss is also the primary cause of amphibians’ numbers falling 
4 
 
(Sodhi et al., 2008). Following the forest clearing, amphibian abundance has suffered 
dramatic reductions. Meanwhile, although under laboratory conditions, it has been 
proven that pH becomes a lethal weapon for amphibian embryos of many species 
(Pierce, 1985), the side effects of acidification are hard to quantify in field 
populations. Therefore, individual acidification has not been taken as a major cause of 
widespread amphibian decline since many probable causes can contribute to the 
decline both at small and large scale (Beebee & Griffiths, 2005). To some degree, 
environmental perturbations like extensive drought and heavy precipitation and 
ﬂooding can have effects on species distributions. What is more, biocides like 
methylisothiazolinone (MIT) impair developmental wound repair and tissue 
regeneration. This combination of factors leads to a poor condition for the surviving 
of amphibians. 
 
Considering the factors affecting the living conditions of amphibians and the dramatic 
decline of amphibian species, carrying out amphibian research is becoming more and 
more urgent and necessary. It is essential to promote the comprehensive utilisation of 
amphibians in the food and medicine industries. At the same time, problems like 
improving active material extraction technologies, obtaining the substances of interest 




1.2 Applications of anurans 
Anurans, namely frogs and toads, play a distinctive role in materia medica. 
Traditionally, their skin and skin secretions have been used for regulating internal 
functions or treating dog bites (Costa-Neto, 1998). In traditional Chinese medicine, 
venenum bufonis (Figure 1), skin secretions from the toad ear glands and epidermal 
glands, has been used for thousands of years and has significant cardiotonic, 
anti-cancer and anti-radiation effects along with stopping pain and inflammation. 
What is more, in modern medicine, venenum bufonis can be used as an anaesthetic 
and for the treatment of oesophageal cancer. Documents also show that skin 
secretions from the giant leaf frog (Phyllomedusa bicolor) have positive effects in 
Alzheimer’s disease and other diseases such as depression, stroke and seizures 
(Amato, 1992).  
 
People in Nagaland, India, have a custom to use frog meat to cover wounds on the 
skin to treat local ulcers and other diseases (Purna Sai, 1995). In some South 
American countries like Brazil and Colombia, the shaman healer performs a Kambô 
ritual on the fresh wounds of the hunters. Skin secretions of Phyllomedusa bicolor are 
applied to the wounds during the ritual which local people firmly believe would bring 







1.3 The diversity of anuran skin peptides 
People realised that the amphibian skin contained a large number of amines and active 
peptides as early as 1976. Indeed, it is hard for other vertebrate tissue to compare with 
amphibian cutaneous tissue in terms of chemical diversity and concentration of these 
active substances.  
 
Anuran skin peptides are grouped into neuroactive peptides and cytolytic peptides 
(König, Bininda-Emonds and Shaw, 2015). These two different peptides are 
subdivided into distinct families considering their biological functions as well as 
structural characteristics. Neuroactive peptides are classified as tachykinins, 
bradykinins, caeruleins, bombesins, opioids, tryptophyllins and miscellaneous 
peptides. These biologically active components are widely distributed across anurans 
(Figure 2).   




Cytolytic peptides can also be called antimicrobial peptides (AMPs) because of their 
abilities to inhibit the growth of a wide range of pathogenic microorganisms and even 
kill them. Meanwhile, some of the cytolytic peptides also show a potent propensity 
against cancer cells, viruses and as antidiabetic agents (Conlon, 2014). The enormous 
number of families of AMPs typically share the same genera or they may come from 
closely related frog species. Amphibian AMPs can be grouped into 7 families 
including the dermaseptins, the phylloseptins, the plasticins, the dermatoxins, the 








Figure 2: Phylogeny showing the distribution of frog skin defensive chemicals.
NPs: neuroactive peptides; x = compound reported from this family; * = not yet investigated
specifically for AMPs. Families in red text have been screened, but apparently lack any compounds.
(König, Bininda-Emonds & Shaw 2015)
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1.4 Amphibian antimicrobial peptides 
Amphibians have a wide distribution on continents like South America, Europe, Asia 
and North America. These numerous species offer a huge variety of bioactive peptides 
working effectively in the innate immune systems of amphibians. These gene-encoded 
active peptides can inhibit the productive growth of microbes such as bacteria, fungi 
and protozoa. What is more, some peptides have been demonstrated to kill cancer 
cells without showing significant haemolytic activity. 
 
1.4.1 Structures and characteristics  
Basically, there are four distinct classifications according to the structures of 
amphibian AMPs: (a) linear α-helical peptides lacking cysteines (Figure 3); (b) the 
cysteine-free linear peptides containing a high proportion of residues such as proline 
or arginine; (c) peptides carrying one disulphide bridge forming a C-terminal loop; (d) 
Peptides containing several disulphide bonds form structures that are predominantly 
β-sheet. Disulphide bonds (Figure 4) are very useful for stabilising the tertiary 

















AMPs are normally ribosomally-synthesised and are made up of 10–50 amino acids 
(Rinaldi, 2002). Most are synthesised in the form of pre-pro-peptides including a 
signal sequence and a C-terminal cationic peptide (Reddy, 2004). The most obvious 
feature of an amphipathic α-helical peptide is the hydrophobic and cationically 
charged surfaces. The mass ranges from 1 kDa to 10 kDa (Rash, 2011). AMPs have 
different structures like linear, cyclic and open-ended cyclic (Daffre, 2008). The 
existence of disulphide bridges may result in functional changes. Most AMPs have 
thermal stability and remain active at 100 ℃for 10-15 min. 
 




1.4.2 The applications of antimicrobial peptides  
Antibiotic resistance leads to an increase in human morbidity and medical costs and is 
therefore considered as a major problem in global public health. Fortunately, some 
AMPs that are produced in epithelial cells or secreted by skin granular glands may 
become potential therapeutic agents. These AMPs are potential antibiotics that act 
quickly and have broad spectra of activities.  
 
Some of the peptides have been shown to be active against Gram-negative and 
Gram-positive bacteria, fungi, enveloped viruses and even cancer cells. In fact, some 
peptides have been used for clinical treatment of impetigo, diabetic foot ulcers and 
Helicobacter pylori infections (Reddy, 2004). 
 
Most of the chemical drugs often inhibit both cancer cells and normal cells with 
greater side effects. However, AMPs can specifically inhibit the growth of certain 
tumour cells, while being harmless to normal human cells. Cecropins, rat AMPs NP21 
and NP22 and the human AMP, HNP21, all show cytotoxic activity against tumour 
cells such as fibroblasts, cervical cancer cells and lung cancer cells (Sang, Zhang & 
Zhuge, 2017). 
In recent years, AMP applications have gradually become hot spots in biology, 
medicine, agricultural science, physiology and other areas of research. They also have 




 Animal husbandry 
Due to the extensive use of traditional antibiotics, on the one hand the 
micro-ecological balance of the animals’ gut is seriously damaged; on the other hand, 
it is easy to stimulate the production of resistant strains, leading to more complex 
livestock and poultry diseases, seriously affecting the quality of animal products and 
human health (Khachatourians, 1998). Broad spectrum antimicrobial agents take full 
advantages in this area. 
 
AMPs can prevent diarrhoea of piglets and improve their adaptation to the fodder and 
environment (Wang et al., 2004). An AMP used in broiler chickens can promote 
growth, improve immunity and the efficiency of fodder. Best of all, these peptides 
have no toxic side effects, no drug residues and even do not pollute the environment. 
Therefore, they are likely to replace antibiotics and become a new type of food 
additive. 
 
 Plant industry 
AMPs also have a broad application prospect in improving antimicrobial abilities of 
plants.  In Li et al.’ study, an engineered magainin analogue peptide was expressed in 
transgenic tobacco, then the plants could resist the pathogen named Erwinia 
carotonora subsp. Carotovora. This test was based on the fact that Myp30 has the 
ability to slow growth of spore germination of the oomycete, Peronospora tabacina, 




 Food industry 
AMPs have the potential value as preservatives in the food industry. These peptides 
have a strong and rapid impact on the inhibition of microbial growth in terms of a 
variety of Gram-positive and negative bacteria that are food related. They can be 
easily digested, and have strong activities in acidic conditions. According to this 
feature, they are suitable for most acidic foods, especially drinks with a good 
solubility and stability. Therefore, AMPs are promising food preservatives (Wang, 
2011). 
 
Nisin has unique anti-infection properties. It has been widely used as a preservative in 
dairy products, meat products and canned fruits and vegetables across more than 50 
countries and regions. In fact, as early as the 1990s, Delves applied Nisin to milk and 
broth to extend its shelf life (Delves, 1990). Since then, Hudaa Neetoo also used Nisin 
and other organic acids to successfully control the harmful effect of Listeria 
monocytogenes on smoked salmon and effectively prolonged its shelf life while 
maintaining its flavour (Neetoo, Ye and Chen, 2008). 
 
Hisako reported that it is possible to control the growth of bacteria and maintain the 
flavour and colour of food by adding only small doses of AMPs (nmol / g) in the 
course of meat processing. Meanwhile, the production of nitrites which are harmful to 




 Aquaculture industry 
With the development of the aquaculture industry, the excrement and the residual 
baits in the aquaculture are more than the degradation capacity of the water 
environment itself, resulting in serious pollution of water resources. If using 
antibiotics to treat the pollution, it will not only cause the ecological imbalance of 
water environment, but also cause drug resistance. Therefore, effective treatment of 
water resources can be achieved by using AMPs with both stable and effective 
antibacterial activities to deal with pathogenic microorganisms in aquatic products 
(Han & Sun, 2009). 
 
 Other applications 
A number of tests have been conducted to investigate their activity against diseases 
such as malaria (Krugliak, 2000) and human immunodeficiency virus (Lorin, 2005). 
Besides, peptides such as magainin and nisin are also considered as potential 
contraceptives (Zairi, 2005) since they can be cytotoxic to sperm. 
 
Recently， researchers added therapeutic agents from peptides to biocompatible 
nanocomposites. These systems have multifaceted advantages when it comes to drug 
delivery because of their submicron size. For instance, Wang combined AMPs with 
cholesterol to form cationic nanoparticles (Wang, 2010). The unique nanoparticles 
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could cross the blood–brain barrier more easily and treat patients carrying fatal 
cryptococcal meningitis and late-stage HIV infection at the same time. 
 
Based on characteristics like low molecular weight, good water-solubility and low 
antigenicity, AMPs can be developed for clinical applications of anti-bacterial, 
antifungal, anti-cancer and as natural contraceptives. AMPs that have specific 
affinities to membranes can be bound to drugs, so that the drugs can act precisely on 
target sites. 
 
1.4.3 Cytolytic activities 
In addition to inhibiting growth of Gram-positive bacteria, Staphylococcus aureus, 
Gram-negative bacteria, Escherichia coli and the yeast pathogen, Candida albicans, 
some peptides can also cause human erythrocyte haemolysis. Red cell damage can 
accelerate cardiovascular and pulmonary diseases. 
 
Membrane lysis is associated with many mechanisms, such as membrane perforation, 
destruction, dissolution, etc. (Shai, 1999; 2002). For example, a haemolytic peptide 
(Ladokhin, 1997) can cause pore formation, and the mechanism of action of cecropin 




1.4.4 Problems exist 
At present, the development of green, efficient, low toxicity and broad spectrum 
antimicrobial agents has attracted global interest. New AMPs have been artificially 
modified based on natural templates to maximise their antimicrobial activity. 
 
AMPs may cause allergic reactions and many natural peptides are haemolytic. In 
addition, this activity is also a problem that must be solved. Activities of the larger 
peptides are closely related to their spatial structures, and even their chirality is also 
an important factor in activity. AMPs obtained by protein synthesis or protein 
engineering, although consistent with natural peptides in primary structure, are not 
guaranteed to be consistent in spatial structures, resulting in differences in activity or 
even no activity at all (Jin & Liu, 2010). 
 
Besides, stability problems in vivo affect the application of AMPs in that protein 
substances used in the body involve many enzyme chemical reactions. Whether AMPs 
in the body will quickly inactivate or not is also a problem worth thinking about.  
 
1.4.5 Other aspects 
Instead of killing frogs, now researchers tend to obtain skin secretions by two 
methods which are electrically stimulating the dorsal region and gently massaging the 
dorsal surface until the secretion becomes visible. Of course, the latter technique is 
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preferred mainly because it reduces the stress of animals and is a humane thing. On 
the other hand, this method creates sustainable usage of frogs since the number of 
frogs is limited and keeps declining during recent years. What is worse, many 
stressors mentioned before may also lead to the alarming decline and extinction crisis 
of amphibians. 
1.5 Aims and objectives of this thesis 
There are not many previous reports on skin secretion peptides of Phyllomedusa 
camba, indicating that many problems remained to be resolved. The situation of drug 
resistant infections is extremely serious, thus making the best of potential novel AMPs 
is of great importance. Additionally, such peptides abundant in their source appear to 
have great market competitiveness and are playing an important role in the study of 
clinical applications. 
In this research, the following aims and objectives were set to be achieved: 
1) Using the method of shotgun cloning, to construct a cDNA library derived 
from skin secretions of Phyllomedusa camba. 
2) Characterise the structures of novel peptides by mass spectrometry (MS) and 
identifying structures by Circular Dichroism Spectra. 
3) Perform bioinformatics analyses on the peptides through the NCBI-BLAST 
programme, then compare the differences and similarities to further the 
recognition of their structures. 




5) Perform functional assays such as antimicrobial assays and haemolysis assays 
to assess the bioactivities of the new peptide. 
6) Gain knowledge of the methods of drug discovery and master how to use a 
variety of related experimental equipment through the whole research process. 
 































Materials and Methods 
2.1 Specimen biodata and secretion harvesting  
Specimens of adult Phyllomedusa camba (Figure 2.1) (n = 3) were commercially 
purchased from Mr. Juan Chavez, Venom Peru Company (PeruBiotech E.I.R.L, 
Huánuco, Peru). The dorsal skin surface was stimulated by gentle transdermal 
electrical stimulation (6V DC; 4 ms pulse-width; 50Hz) through platinum electrodes 
for two periods of 20s duration or the skin secretion was obtained via mild squeezing 
and massaging of the glands. The viscous white skin secretion was washed from the 
skin using deionised water, snap-frozen in liquid nitrogen, lyophilised and stored at 
-20°C prior to analysis. All the procedures were subject to ethical approval and 




Figure 2.1 Phyllomedusa camba 
(https://en.wikipedia.org/wiki/Phyllomedusa_camba) 
 
2.2 Molecular cloning 
Lyophilised skin secretin was dissolved in stabilisation buffer. Magnetic oligo-dT 
beads were then employed to isolate the polyadenylated mRNA as described by the 
manufacturer (Dynal Biotech, UK). The isolated mRNA was converted to more stable 
cDNA using reverse transcriptase. This cDNA was subjected to 3’-RACE procedures 
to obtain full-length skin peptide precursor nucleic acid sequence data by employing a 
SMART RACE Kit (Clontech, UK) as described by the manufacturer. Briefly, the 
3’-RACE reactions employed a degenerate sense primer (S1; 5′- 
ACTTTCYGAWTTRYAAGMCCAAABATG-3′ (Y=C + T, W = A + T, R = A + G, 
M = A + C, B = T + C + G) that was designed to a highly-conserved domain of the 
5’-untranslated region of previously-characterised skin AMP-encoding cDNAs from 
phyllomedusa frogs. 
 
2.2.1 mRNA isolation  
A Dynabeads
®
 mRNA DIRECT™ Kit (Invitrogen, Lithuania) was utilised in mRNA 
isolation. The poly A tail of poly A mRNA from the sample can hybridise to the 




 Preparation of skin secretion 
Five mg of lyophilised skin secretion were weighed and transferred into an Rnase-free 
1.5 ml tube with 1 ml of Lysis/Binding buffer (Dynal Ltd, UK). Then, the 1.5 ml tube 
was vortexed for 20 min in total and placed on cold ice for several seconds at intervals 
of three min to obtain the undegraded mRNA. Finally, the lysate solution was 
centrifuged at 14,000 × g for 5 min in an Eppendorf Centrifuge 5424 (Eppendorf, 
Germany) to remove the debris. The supernatants were prepared and stored cold until 
the beads were ready. 
 
 Preparation of Dynabeads® Oligo (dT)25 beads 
Two hundred and fifty μl of thoroughly resuspended Dynabeads® Oligo (dT)25 beads 
(5 mg/ml) were transferred into a 1.5 ml RNase-free tube. The tube containing the 
beads was placed on a magnet rack (Dynal MPC-S) for 2 min. Then, the supernatants 
were removed and discarded as cleanly as possible when the supernatants were 
clarified. After that, 250 μl Lysis/Binding Buffer were transferred into the 1.5 ml tube 
to wash the beads by gently shaking. Finally, the supernatants were removed and 
discarded completely from the 1.5 ml tube on the magnetic rack when the lysate was 
well prepared to avoid drying the beads and lowering beads capacity. 
 
 Hybridisation between the poly A tail of mRNA and bead-bound oligo-dT  
The supernatants from the lysate solution were transferred into the 1.5 ml tube 
containing prepared beads which were combined with oligo-dT on the surface by 
24 
 
covalent binding. The mixture of lysate and beads was blended by slowly and gently 
shaking for 20 min (2 min shaking and 3 min on ice , repeated four times) at room 
temperature, which made the poly-A tail of mRNA hybridise to the bead-bound 
oligo-dT through A-T base pairing. Finally, the tube was placed in the magnet rack 
for 5 min to make sure that the supernatant was clean and then it was removed. The 
intact mRNA was isolated from the secretion and retained on the surface of the beads. 
 
 Washing 
The beads/mRNA complex was washed by slowly and gently using 500 μl Washing 
Buffer A three times to eliminate impurities. The beads were separated from the 
washing solution and the washing solution was discarded on the magnetic rack after 
each washing step. Similarly, the beads/mRNA complex was washed by slowly using 
500 μl Washing Buffer B two times to eliminate the lithium salts.  
 
 Elution 
A volume of 18 μl of cool elution solution (Tris-HCl, 10mM) was added drop by drop 
into the 1.5 ml tube containing the well-washed beads and the 1.5 ml tube was flicked 
gently to make every droplet carry the beads down to the bottom until all the solution 
ran through. Then, the 1.5 ml tube was incubated in a heating block (Grant, 
Cambridge, UK) at 80°C for 2 min to remove the mRNA from the beads. All 
supernatants were subsequently transferred into a 0.2 ml RNase-free PCR tube on the 
magnetic rack as soon as possible to avoid mRNA readsorbing onto the beads. Finally, 
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the 0.2 ml PCR tube was cooled on ice for 2 min and then the solution was allocated 
into five chilled-prepared 0.2 ml PCR tubes which included 4 μl volume for three 
PCR tubes and 3 μl volume for two PCR tubes, respectively (Figure 2.2.1.1). 
 
 




2.2.2 cDNA library construction 
A BD SMART™ RACE cDNA Amplification Kit (BD Bioscience Clontech, UK) 
was used in cDNA library construction and primary cDNA amplification. 5’ RACE 
Ready cDNA was synthesised using a 5’-RACE CDS Primer and the BD SMART 
II™ A Oligonucleotide which contained a terminal stretch of G residues to pair with 
the dC-rich cDNA tail at the end. 3’-RACE-Ready cDNA was synthesised using 
3’-RACE CDs Primer by a reverse transcription reaction. 
 
 Preparation of sample mixture 
 Preparation of mixture for 3’ RACE Ready cDNA synthesis 
The following components were combined and mixed completely by pipetting in 
three 0.2 ml PCR tubes respectively. One extra volume of reagents was calculated and 
added to ensure sufficient volume for the RT-PCR reaction (Table 2.2.2.1).  
Table 2.2.2.1 The components of the 3’ RACE cDNA reaction 
Component Final Volume Final Concentration 
RNA sample 4 μl 40% 
3’-RACE CDS Primer 1 μl 1 μM 
dNTP Mix (10 mM) 1 μl 1 mM                                                                                                                    
DTT (20 mM) 1 μl 2 mM 
5X First-Strand Buffer,30mM MgCl2 2 μl 1 X 
BD Reverse Transcriptase 1 μl 10 Unit/μl 





 Preparation of mixture for 5’ RACE Ready cDNA synthesis 
The following components were combined and mixed completely by pipetting in two 
0.2 ml PCR tubes. One extra volume of reagents was calculated and added to ensure 
sufficient volume for the RT-PCR reaction (Table 2.2.2.2).  
Table 2.2.2.2 The components of the 5’ RACE cDNA reaction 
Component Final Volume Final Concentration 
RNA sample 4 μl 40％ 
5’-RACE CDS Primer (10 µM) 1 μl 1 μM 
SMART II (10 µM) 1 μl 1 μM 
dNTP Mix (10 mM) 1 μl 1 mM 
DTT (20 mM) 1 μl 2 mM 
5X First-Strand Buffer,30mM MgCl2 2 μl 1 X 
Reverse Transcriptase 1 μl 10 Unit/μl 
*The Master Mix includes dNTP Mix, DTT and 5X First-Strand Buffer for 5 
reactions. 
 
 Reverse transcription polymerase chain reaction (RT-PCR) 
Five PCR tubes, containing sample mixture, were micro-centrifuged and incubated in 
the heating block at 70°C for 2 min to combine the primer and templates. Then, five 
0.2 ml PCR tubes were cooled ice for 2 min. After that, 4 μl prepared Master Mix was 
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divided into each 0.2 ml PCR tube and pipetted completely. Subsequently, 1 μl 
Reverse Transcriptase was added into each 0.2 ml PCR tube and pipetted completely. 
After adding all solutions, five 0.2 ml PCR tubes were micro-centrifuged to collect all 
contents at the bottom without bubbles and incubated in the thermal cycler (Applied 
Biosystems, UK) at 42°C for 1.5 h to complete the reverse transcription reaction. 
 
 Concentration, dilution and fault correcting 
Fifty μl of deionised water were added into each PCR tube to lower the concentration. 
Then, five PCR tubes were incubated in the thermal cycler at 72°C for 7 min to 
correct the faults in the reaction and kill some enzymes such as Reverse Transcriptase. 
At this point, 3’- and 5’-RACE Ready cDNA templates were obtained and stored at 
-20°C in the freezer.  
 
2.2.3 Polymerase chain reaction (PCR) amplification of cDNA 
 Preparation of mixture for RACE-PCR reaction 
The following components were combined and mixed completely by pipetting and an 
extra volume was calculated and added to ensure sufficient volume for the 
RACE-PCR reaction (Table 2.2.3.1). 
Table 2.2.3.1 The components of one RACE-PCR reaction 
Component 
Final 
Volume Final Concentration 
29 
 
PCR-Grade water 2.6 μl - 
10X BD Advantage 2 PCR Buffer 1 μl 1 X 
dNTP Mix (10 mM) 0.2 μl 0.2 mM 
NUP Primer (20 µM) 0.5 μl 1 μM 
Sense Primer (20 µM) Anti-sense primer 0.5 μl 1 μM 
50 X BD Advantage 2 Polymerase Mix 0.2 μl 1 X 
3’ RACE-Ready cDNA templates 10 μl  
*The 3’ RACE-Ready cDNA templates were substituted with water in the negative 
control. 
*The Master Mix includes PCR-Grade water, 10X BD Advantage 2 PCR Buffer,   
dNTP Mix, NUP Primer, Sense Primer and BD Advantage 2 Polymerase Mix for 4 
reactions. 
 
 3’ RACE-Ready cDNA amplification  
Twenty μl of Master Mix were allocated into four well-prepared PCR tubes and 10 μl 
of 3’ RACE-Ready cDNA templates were added into two PCR tubes. 10 μl of 
PCR-Grade water were added into another two PCR tubes as negative controls. 0.5 μl 
NUP primer (supplied with the kit) and 0.5 μl specific degenerate sense primer (S1; 
5′- ACTTTCYGAWTTRYAAGMCCAAABATG-3′ (Y=C + T, W = A + T, R = A + G, 
M = A + C, B = T + C + G) were added into each PCR tube. The degenerate primer 
was designed based on the highly-conserved 5’-untranslated region of 
previously-characterised homologous peptide cDNAs from Phyllomedusa camba. All 
30 
 
of the reagents were pipetted completely and micro-centrifuged to collect all contents 
at the bottom without bubbles. Finally, the RACE-PCR programme with a gradient 
temperature was set and commenced in the thermal cycler. The appropriate annealing 
temperature was determined in the RACE-PCR reaction. Three steps of PCR reaction 
with different conditions were set up and each cycle included 94°C denaturation for 
30 s to obtain single-stranded DNA templates, 58°C annealing for 30 s between 
primer and single-strand DNA templates and 72°C extension for 3 min. All the 
procedures were repeated over 40 thermal cycles to obtain double-stranded DNA 
amplification. The annealing temperature in one group included one 3’ RACE-Ready 
cDNA template and one negative control at 53°C, whereas it was set at 55°C in 
another group. All of the four samples after RACE-PCR reaction were stored at -20°C 
in the freezer (Figure 2.2.3.1). 
 





2.2.4 Agarose gel electrophoresis 
Gel electrophoresis is a technique to separate DNA fragments, based on their sizes 
and charges. 
 
 Preparation of 1.5% agarose gel 
0.45 g agarose (Invitrogen, UK) was transferred into a 200ml flask with 35 ml of 
freshly prepared 1X Tris/Borate/EDTA (TBE) buffer (Invitrogen, UK). The flask was 
heated in a microwave oven without foaming until all the agarose was dissolved 
completely, and then it was cooled for several minutes. 2.5 µl of 10 mg/ml Ethidium 
Bromide (EB) (Sigma-Aldrich, USA) were added into the flask when the agarose had 
cooled to about 60 C to bind to the DNA and make the DNA visible under ultraviolet 
light. The flask was swirled gently to ensure good mixing of contents. Then, the 
molten agarose was poured into a gel tray which was placed after cooling, into a gel 
electrophoresis tank with a sample comb. The agarose was then allowed to solidify 
fully at room temperature for about 40 min. After the gel became solid, the comb was 
gently removed, then the TBE buffer was poured into the gel tank until just above the 
surface of the gel. 
 
 Sample loading and electrophoresis 
Two and half μl of a standard DNA ladder (Invitrogen, UK) composed of several 
fragments of known molecular weight, were loaded carefully into the first lane of the 
agarose gel to measure the size of DNA fragments. 1.5 μl of samples and 0.5 μl of 
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loading dye (0.25% bromophenol blue, 15% Ficoll 400 in TAE) were mixed well and 
loaded carefully in the other lanes in order. After that, the electrophoresis was run at 
90 v and the samples travelled through the gel from the negative electrode to the 
positive electrode for 30 min until the yellow colour indicator reached two-thirds of 
the gel. Finally, the power was stopped and the gel was transferred into a large weigh 
boat for later detection of bands. 
 
 Detection of bands and gel analysis 
The electrophoresis gel was placed under the UV trans-illuminator BioDoc-It
®
 
Imaging System (NVP, Cambridge, UK) and a photographic image was recorded as 
the result. The DNA bands of the samples were compared with those of the ladder to 
determine whether the DNA amplification was successful or not. The 1X TBE Buffer 
was recycled and the samples were stored at -20°C in the freezer. 
 
2.2.5 PCR product purification 
An E.Z.N.A.
®
 Tissue DNA Kit (Omega, Norcross, UK) was employed in PCR 
product purification, in which DNA was bound to silica-based filter membranes 
during washing steps and eluted for collection (Figure 2.2.5.1). 
 






 DNA binding with the filter membranes 
The DNA amplification samples from the previous steps were mixed together and 
transferred into a 1.5 ml DNase-free tube. Then, 87 μl Buffer CP were added into the 
1.5 ml tube where five volumes Buffer CP corresponded with one volume PCR 
product according to the weight of DNA product. After pipetting evenly and 
completely, the liquid in the PCR tube was transferred into the center of the cartridge. 
The cartridge was centrifuged at 8000 × g for 1 min. The liquid was discarded and 
700 μl Washing Buffer was added into the cartridge. Then the cartridge was 
centrifuged at 8000 × g for 1 min. The liquid was removed and 500 μl Washing 
Buffer was added into the cartridge. Then the cartridge was centrifuged at 8000 × g 
for 1 min.The liquid was discarded and the cartridge was centrifuged at 8000 × g  for 
2 min to remove the ethanol completely. 30 μl of distilled Water was added to the 
center of the cartridge and a sterile 1.5 ml tube was used to hold the contents. The 
tube was incubated at room temperature for 2 min and then centrifuged at 15000 × g 
for 1 min. The tube contents were concentrated in the concentrator for 50 min. Then 










-T Easy Vector (Promega, USA) kit was used for ligation, 
transformation, blue and white colony screening and isolation of recombinant DNA 
reactions. The DNA with A at both ends of the strand could bind to and insert into the 
site of the pGEM
®
-T Easy Vector (50 ng/μl) with T through A-T based pairing.  
 
1) 7 μl of PCR reagents were added into the tube containing the lyophilized DNA 
with gentle pipetting. 
2) 2.5 μl 2X Rapid Ligation Buffer, 0.5 μl T4 DNA Ligase and 0.5 μl pGEM®-T Easy 
Vector was added into a sterile PCR tube. The pGEM®-T Easy Vector was briefly 
centrifuged before use. 
3) 1.5 μl DNA sample from 1) was added into the mixture from 2) with gentle 
pipetting. 




The recombinant vectors were transformed into the competent cells and selected by 









 Preparation of LB/ampicillin/IPTG/X-Gal plates 
LB agar (Invitrogen, UK) was weighed and dissolved in 200 ml double deionised 
water in a 400 ml glass bottle. Then, the bottle was autoclaved for sterilisation. 550 μl 
ampicillin (Roche, USA) were added into the heated agar solution and mixed 
completely. This was to select the bacteria with the specific antibiotic resistance gene. 
Then, 11 ml of melted agar solution was aliquoted and poured into each Petri dish. 
After the solidification of agar, 100 μl IPTG (Promega, USA) as an inducer were 
added and spread over the surface evenly which induced the expression of the lacZ 
gene. Subsequently, 20 μl X-Gal (Promega, USA) as a chromogenic substrate, were 
added and spread over the surface completely in a dark environment and this reacted 
with β-galactosidase and was detected by a colour change. Finally, all the plates were 
incubated upside down keeping the water inside the agar for 45 min at room 
temperature, and then the plates were ready for cell or bacterial culture. In addition, 
the LB agar plates could be stored at 4°C for up to one month. 
 
 Transformation  
1) Ligation product were transferred into a sterile 1.5 ml tube and then set on ice. 
2) JM109 competent E. coli cells were removed from the -80°C freezer and 
immediately placed on ice for 4 min to thaw. 
3) 50 μl of JM109 cells were added into a 1.5 ml tube containing ligation product with 
no pipetting. Then the tube was incubated on ice for 20 min. 




5) 950 μl of Super Optimal Broth (SOC) Medium were added to the mixture gently. 
Then the tube was incubated at 37°C for 150 min. 
6) A solution of 6.4 g LB Agar in 200 ml DD water was made and then autoclaved.  
7) 12 ml of agar solution were added into Petri dishes then these were incubated at 
37°C for 30 min. 
8) 100 μl isopropyl-β-d-thiogalactoside (IPTG) and 20 μl Xgal were added onto each 
plate and a “hockey stick” was used to spread the reagents. 
9) 100 μl of SOC solution were added onto each dish and spread evenly prior to 
incubation at 37°C for 24 h. 
 
2.2.8 Blue and white colony screening 
There were three kinds of colonies found growing on the LB/ampicillin/IPTG/X-Gal 
plates from the previous procedures including white colonies, blue colonies and white 
colonies with a blue dot. Pure white colonies and white colonies with a blue dot, in 
which the vectors were inside the competent cell and contained the recombinant DNA, 
were selected and subcultured in the solid medium for further identification. The 1.5 
cm length squares were divided by drawing lines at the bottom of the Petri dish, then 
the pure white colonies and white colonies with blue dots were picked up and 
transferred into three new LB/ampicillin/IPTG/X-Gal plates by streaking without 
touching the edge of the lines using an inoculating loop under a sterile environment. 
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All of the three plates were incubated upside down at 37°C overnight (16-24 h) for 
subculture and further selection. 
 
2.2.9 Isolation of recombinant DNA by cloning PCR 
A single DNA was isolated and amplified by the cloning PCR reaction, in which the 
M13 Forward Primer (5’-GTAACGCCAGGGTTTTCCCAG-3’) and M13 Reverse 
Primer (5’-TGTGAGCGGATAACAATTTCAC-3’) bound to the 5’ and 3’ ends of 
inserted DNA, respectively by use of an Advantage
®
 2 PCR Kit (Clontech Inc, USA). 
 
1) 20 μl of PCR water were added into autoclaved 0.5 ml tubes and a sample from 
each white colony was transferred into these tubes. 
2) The tubes were incubated at 100°C for 5 min and then set on ice for another 5 min. 
3) Then the mixtures were centrifuged at 8000 × g for 5 min. 
4) A master mix was then made (Table 2.2.9.1).  
5) The master mix was placed in PCR tubes. Then 2.5 μl of supernatant from each 
sample were added into each tube.  
6) 0.25 μl of Taq Polymerase was added into each PCR tube. The contents of tubes 
were gently mixed by pipetting. 
7) The tubes were then incubated in a PCR machine (Applied Biosystems, USA) for 
32 cycles of 94 °C initial denaturation for 30 s, 55 °C annealing for 30 s and 72 °C 
extension for 3 min. 
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Table 2.2.9.1 Master mix for PCR of Plasmid cDNA 
Component 
Final 
Volume Final Concentration 
dNTP Mix 1 μl 0.2mM 
PCR-Grade water 31 μl - 
Cloning PCR Buffer 10 μl 1 X 
M13 Forward Primer(20µM) 2.5 μl 1 μM 
M13 Reverse Primer(20µM) 2. 5 μl 1 μM 
 
2.2.10 Agarose gel electrophoresis analysis 
1) 0.45g agarose was mixed with 35 ml 1XTBE Buffer. The mixture was rotated and 
heated in a microwave until transparent. 
2) 2.5 μl EB was then added into the agarose.  
3) The agarose was then poured into the grooves of the gel analysis device. All the 
bubbles in the mixture were carefully removed. 
4) 40 min later, 2.5 μl of DNA ladder were added into the first well. 1.5 μl from each 
sample tube were added into separate wells.  
5) The gel analysis device was run at 90 V for 30 min, after which, the power was 





2.2.11 Selected PCR product purification 
An E.Z.N.A. 
®
 Tissue DNA Kit (Omega, Norcross, UK) was employed in PCR 
product purification, in which DNA was bound to silica-based filter membranes 
during washing steps and eluted for collection. 
 
1) Selected DNA products were transferred into sterile 1.5 ml tubes and mixed with 
250 μl CP buffer. 
2) The liquid was transferred into the center of the cartridge. Then the cartridge was 
centrifuged at 8000 × g for 1 min. 
3) The liquid was discarded and 700 μl Washing Buffer was added into the cartridge. 
Then the cartridge was centrifuged at 8000 × g for 1 min. 
4) The liquid was removed and 500 μl Washing Buffer was added into the cartridge. 
Then the cartridge was centrifuged at 8000 × g for 1 min. 
5) The liquid was removed and the cartridge was centrifuged at 8000 × g for 2 min to 
remove the ethanol completely. 
6) 20 μl of DD Water were added to the center of the cartridge and a sterile 1.5 ml 
was used to hold the contents. The tube was incubated at room temperature for 2 
min and then centrifuged at 8000 × g for 1 min. 
7) The tube contents were then concentrated in a concentrator for 40 min. Then the 




2.2.12 DNA sequencing reaction 
A BigDye
®
 Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, California, 
USA) was utilised in the DNA sequencing reaction in which the sequence was 
detected by an ABI 3730 automated sequencer (Applied Biosystems, USA). 
 
 Preparation of mixture for sequencing PCR reaction 
Four optimal DNA samples were chosen for the sequencing reaction and 10 μl of 
M13 Forward Primer were diluted in 52.5 μl PCR-Grade water. The following 
components were combined and mixed completely by pipetting, and an extra volume 
was calculated and added to ensure sufficient volume for the sequencing PCR reaction 
(Table 2.2.12.1).  
Table 2.2.12.1 The components of a sequencing PCR reaction 
Component Final Volume Final Concentration 
PCR-Grade water 12.4 μl - 
5X Sequencing Buffer 3.57 μl 1 X 
M13 Forward Primer 1.14 μl 0.8 μM 
Terminator Ready Reaction Mix  2.86 μl 13.68% 
DNA template  2.5 μl 10-1000 ng 
*The Master Mix includes PCR-Grade water, 5X Sequencing Buffer, M13 Forward 
Primer and Terminator Ready Reaction Mix for 4 reactions. 
 
 DNA sequencing reaction 
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Master Mix and 2.5 μl sample were aliquoted into 0.2 ml PCR tubes and the 
sequencing PCR reaction was set and commenced using the following programme. 
Each cycle in the thermal cycler consisted of: 96°C denaturation for 20 s, 55°C 
annealing for 10 s and 60°C extension for 4 min. Cycles were repeated 26 times in 
total for 2h 15min. Finally, the four sequencing products were stored at -20°C in the 
freezer. 
 
2.2.13 Extension product purification by ethanol  
 Reagent preparation 
One ml PCR-Grade water and 19 ml ethanol were mixed completely to produce a 95% 
ethanol preparation and 6 ml PCR-Grade water and 14ml ethanol were mixed for the 
70% ethanol preparation. 
 
 Ethanol purification 
Seventy-two μl of 95% ethanol were added into the PCR tube with sequencing 
reaction products and pipetted vigorously. After that, all the solutions were transferred 
into a 1.5 ml tube with 10 μl PCR-Grade water. Each of the 4 tubes was vortexed for 
30 s and kept at room temperature for 20 min and then centrifuged at the maximum 
speed of 8000 × g for 20 min. Immediately after this, the supernatants were discarded 
as cleanly as possible. Similarly, 260 μl 70% ethanol were added into each 1.5 ml 
tube with sequencing reaction products and mixed, vortexed for 30 s and centrifuged 
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again as before. Then the supernatants were discarded quickly. Afterwards, a 1 min 
cooling step and a 1 min heating step at 95°C were repeated 3 times. Finally, the 
contents of the 1.5ml tubes were concentrated for 3 h to dry the DNA and to drive the 
ethanol away. Finally, the 4 samples were stored at -20°C in the freezer. 
 
2.2.14 Sequencing 
Ten μl HiDi (highly deionised-formamide) were added to each DNA sample which 
had been concentrated for 1 h before use. Then, the 1.5ml tubes were vortexed and 
then centrifuged briefly as before. Afterwards, the tubes were heated to 95°C for 4 
min in the heating block and cooled on ice for 3 min. Subsequently, 9 μl of 
well-prepared mixture sample was loaded into the 96-well plate in odd or even rows. 
Finally, the sequencing results were obtained using an ABI 3730 automated sequencer 
(Applied Biosystems, USA). The elongation of DNA strands in the solution was 
terminated by the modified ddNTPs randomly and detected by fluorescence.  
 
 Sequence analysis  
The exact recognition site with the sequence AATTCGATT from the pGEM
®
-T Easy 
Vectors and a series of guanosine endings were recognised in the results. The middle 
sequences were regarded as targeted sequence and translated into amino acid 
sequence on the website Expasy (http://web.expasy.org/translate/). At this point, the 
putative nucleotide and translated open reading frame amino acid sequences of cloned 
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cDNA encoding precursor were obtained.  
 
2.3 Solid phase peptide synthesis 
The novel mature peptide was chemically-synthesised by solid phase 
Fluorenylmethoxycarbonyl (Fmoc) chemistry in a Tribute automated solid-phase 
synthesiser (Protein Technologies, Inc, Tucson, AZ, USA). The mechanism of SPPS is 
one of repeated cycles of deprotection-wash-coupling-wash (Figure 2.3.1). The 










2.3.1 Peptide synthesis 
A Tribute Peptide Synthesiser (Protein technologies, USA) was used for solid-phase 
peptide synthesis (Figure 2.3.1.1). Before the carousel was loaded with amino acid 
vials, the inline solvent filters and source of nitrogen needed to be checked as were 
the reagent bottles to ensure that sufficient reagents were present for the synthesis. 
The bottles needed to be pressurised before the reagent vessels and amino acids were 
loaded. Synthesis was started through the pressing of the run button after the coupling 
programme was initiated. 
 






The weights of catalyst 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) and dry amino acids in equal proportion and in 
four-fold molar excess, were calculated and weighed into acetone-cleaned amino acid 
vials. Then, 0.3 mmol rink amide resin which contained an amide group for the 
C-terminus was also weighed into the reaction vessel. During the peptide synthesis 
reaction, the reaction vessel and pipeline were washed by dimethylformamide (DMF) 
first, and then the Fmoc protecting groups were deprotected using 20% (v/v) 
piperidine in DMF. Each amino acid residue was activated and coupled using 11% 
(v/v) N-Methylmorpholine (NMM) in 89% (v/v) DMF combined with activator 
HBTU. After that, the peptide was synthesised from C-terminal to N-terminal by the 
PS4 synthesiser. Finally, degassed dichloromethane (DCM) was employed for 
washing the peptide/resin complex after the synthesis reaction. The peptide/resin was 
dried in a vacuum desiccator overnight. 
 
2.3.2 Peptide cleavage and rotary evaporation 
1) The dried resin was weighed and transferred into a 50 ml round-bottomed flask. 
2) 28.2ml 94% (v/v) trifluoroacetic acid (TFA), 0.6ml 2% (v/v) ethanedithiol (EDT), 
0.6 ml 2% (v/v) water and 0.6 ml 2% (v/v) thioanisole (TIS) were added into the 50 




3) The flask was removed to a magnetic stirrer for 2.5 h at room temperature. 
4)  After stirring, the cleavage solution was filtered using a Buchner funnel into a 50 
ml round-bottomed flask and then the resin was washed by a volume of DCM. 
5) The filter liquid was concentrated by a rotary evaporator in a water bath until 4-5 
ml remained. 
6) The concentrated liquid was transferred to a 50 ml centrifuge tube. 
7) 45-50 ml of Et2O was added to the tube and the tube was left covered by silver 
paper with holes at room temperature, to complete the oxidation reaction for 3 days 
to form the disulphide bonds  if required (the tube was shaken 2-3 times/day and 
50 ml of Et2O were added). 
 
2.3.3 Peptide washing 
1) The tube was centrifuged at 5000 × g for 5 min and the supernatant was discarded. 
2) A volume of Et2O was added to the tube and then the tube was centrifuged. This 
was repeated three times. 
3) The supernatant was discarded and the tube was covered by silver paper with holes 
and placed in a vacuum desiccator to dry overnight.  
 
2.3.4 Peptide lyophilisation  
1) 30 ml of Buffer B (0.05%/29.95/70.0 (TFA/water/Acetonitrile) (v/v/v)) were added 
to the tube which was then vortexed to dissolve the peptides. 
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2) The tube was then frozen in liquid nitrogen for 10-20 min. 
3) This tube was then placed into an Alpha 1-2 freeze-drying system (Martinchrist, 
Germany) to be lyophilised for 72 h. 
4) The lyophilised peptide was stored at –  
The molecular weight of the peptide was calculated by Peptide Property Calculator 
(https://www.genscript.com/tools/peptide-property-calculator).  
 
2.4 Reversed-phase high performance liquid chromatography (HPLC) 
 
High performance liquid chromatography (HPLC) is widely used to separate, identify 
and quantify each compound in a mixture through use of a stationary and a mobile 
phase. HPLC works through pumping a pressurised liquid mobile phase and a sample 
mixture through a column filled with a solid phase stationary phase. Depending on 
different absorptive characteristics, the components of the sample mixture are 
separated from each through interaction with the solid support and elution at different 
concentrations of mobile phase. 
 
Reverse phase HPLC (RP-HPLC) was employed to separate the skin secretion 
components into fractions. The RP-HPLC contains a non-polar stationary phase and 
an aqueous, moderately polar mobile phase. The mechanism of RP-HPLC is 
hydrophobic interaction between sample components and stationary phase. A 
representative HPLC system consists of pumps, a sampler, column, detector, fraction 
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collector and data analysis system (Figure 2.4.1). 
 




10 mg of crude lyophilised peptide was weighed and diluted in a 15ml universal tube 
with 5 ml Buffer A and 5 ml Buffer B. Then, the 15ml universal tube was vortexed 
and centrifuged at the maximum speed for 15 min. The clear supernatants were 
transferred into another 15ml universal tube. An analytical reverse phase HPLC 
Jupiter C5 column (250nm * 4.6 mm, Phenomenex, UK) was washed with Buffer B 
for 30 min and equilibrated in Buffer A for 30 min before use. Subsequently, 1 ml of 
clear supernatant was pumped onto the Jupiter C5 column on a Cecil Adept CE4200 
HPLC system (Cecil, Cambridge, UK) for peptide elution and purification with 
214nm wavelength detection. The peptide was eluted from the column with a linear 
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gradient from 100% Buffer A to 100% Buffer B over 80 min at a flow rate of 1 
ml/min. The fractions were collected in polypropylene tubes (Sarstedt, Germany) at 
every peak using an Amersham Biosciences Frac-920 fraction collector and utilised 
for identification.  
 
2.5 Peptide analysis by matrix-assisted laser desorption ionisation 
time-of-flight mass spectrometry  
MALDI-TOF mass spectrometry was used for peptide identification by mass analysis 
using a linear time-of-flight mass spectrometer (Voyager DE, PerSeptive Biosystems, 
Framingham, MA, USA) in positive detection mode. Internal mass calibration was 
verified using the standard peptides corresponding with standard molecular masses to 
ensure high accuracy of ±0.1%. 2 μl of HPLC fractions were loaded and spotted onto 
the MALDI ground-steel target plate, and 1 μl excess matrix solution (10 mg/ml) 
which contained alpha-cyano-4-hydroxycinnamic acid (CHCA) diluted in 
acetonitrile/TFA/water (70/0.02/30, v/v) was also loaded and spotted after drying the 
fractions. The samples were ionised and flew through the electrical field in the 
instrument to reach the detector. The peptide was identified by mass measurement, 
which depended on its mass-to-charge (m/z) ratio. Finally, the pure peptide was 
obtained and subjected to lyophilisation and biological activity assay. 
 
Besides, some useful bioinformatics websites can be utilised in prediction and 
analysis of the physicochemical properties and secondary structure of the peptide, 
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such as HELI-QUEST (http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py) and 
NCBI-BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
2.6 Antimicrobial assays 
Three standard microorganisms were used in these assays including the Gram-positive 
bacterium, Staphylococcus aureus (S. aureus, NCTC 10788), the Gram-negative 
bacterium, Escherichia coli (E.coli, NCTC 10418) and the pathogenic yeast, Candida 
albicans (C. albicans, NCPF 1467), to assess antimicrobial and bactericidal activity of 
the peptide. The MIC assay is designed to test the minimum visible growth-inhibitory 
concentration of microorganisms and is reliable, rapid and inexpensive. The MBC 
assay is designed to test the minimum concentration of antibiotic that is lethal to a 




2.6.1 Microorganism inoculation 
1) Beads of each of the three microorganisms were removed from the -20℃ freezer 
and placed into McCartney bottles of 100 ml Muellar Hinton Broth.  
2) The flasks with beads were incubated in an orbital shaking incubator (Stuart, UK) 
overnight (16 - 20h) at a speed of 150 rpm at 37℃. For each microorganism, two 
McCartney bottles with 20ml MHB were placed into a 37℃ incubator to be 
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warmed up overnight. 
 
2.6.2 Peptide preparation 
The sample was initially dissolved in a stock solution of 1024 µM and subsequently 
double-diluted to achieve final concentrations of the peptide from 512 to 1 µM.  
 
2.6.3 Subculture 
1) The next day, 500 µl of each microorganism culture were transferred into 
pre-warmed McCartney bottles with MHB and replaced into the 37℃ shaking 
incubator until the logarithmic phase of microorganism growth was reached. (Table 
2.6.3.1). 
Table 2.6.3.1 The appropriate OD values for the three microorganisms used. 
Organism 
   Subculture incubation 
time 
OD Concentration (cfu/ml) 
S. aureus 1.5 h 0.2 10
8
 
E. coli 1.0 h 0.4 10
8
 
C. albicans 2.0 h 0.15 10
6
 
*The OD was measured by a UV spectrophotometer at λ=550nm. 
* cfu= colony-forming units. 
 
2) 100 µl of S.aureus and E.coli subcultures were added into 19.9 ml fresh 
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pre-warmed MHB and mixed well by pipetting. The C.albicans subculture was 
ready to use. All three microorganism subcultures were used at 10
6
 cfu /ml. 
 
2.6.4 Minimum inhibitory concentration (MIC) measurements  
1) Samples and controls were arranged in the 96-well plate with 5 replicates of each. 
Control: 100 µl sterile MHB 
Samples: 50 µl peptide solution + 50 µl culture 
Blank: 100 µl culture  
2) The 96-well plate was placed in the shaking incubator for 5 min to make the 
mixture well-distributed and was then incubated at 37℃ overnight. 
3) The next day, the inhibition of microorganism growth was measured by the 
absorbance at 550 nm using the Synergy HT plate reader (BioTek, USA). 
 
2.6.5 Minimum bactericidal concentration (MBC) measurements 
1) 10 µl of supernatant from each clear well on MIC plates, were dropped onto the 
MHA plate. The MHA plates were then incubated at 37℃ overnight. 
2) The next day, the plates were examined for microorganism growth. The MBC value 




2.7 Haemolysis assay 
2.7.1 Peptide and control preparation 
1) Synthetic peptide was weighed and dissolved in sterile PBS to a concentration of 
1024 µM 
2) This was then double-diluted to achieve the following concentrations: 512, 256, 
128, 64, 32, 16, 8, 4, 2, 1 µM. The peptide solutions were kept in centrifuge tubes 
until required. 
3) 22 μl Triton X-100 (Sigma Aldrich, St. Louis, MO, USA) were diluted in 1078 μl 
PBS solution as a positive control in which 1% (v/v) non-ionic detergent Triton 
X-100 (Sigma-Aldrich) can produce a 70% haemolytic effect.  
4) PBS solution was regarded as a negative control (blank control) for the comparison 
of non-haemolytic effects.  
5) 22 μl DMSO was diluted in 1078 μl PBS solution as a vehicle control to assess the 
influence of 1% (v/v) DMSO solution on the erythrocytes.  
 
2.7.2 Horse blood preparation 
Two ml of fresh defibrinated horse blood (TCS Biosciences Ltd, Buckingham, UK) 
were transferred into a 50 ml universal tube and centrifuged at 100 × g for 5 min to 
separate the serum and erythrocytes. Then, the cloudy supernatants were discarded 
completely and 30 ml of PBS solution were added. Several washing steps were 
repeated until the supernatants were clear. Then, the supernatants were discarded as 
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cleanly as possible and PBS solution was refilled to the 50 ml volume. Finally, gentle 
shaking was needed to obtain an even 4% (v/v) erythrocyte suspension.  
 
2.7.3 Haemolysis assay 
1) 200 µl of peptide sample solution were added into a sterile tube with 200 µl of red 
blood cell suspension. 5 replicates were made for each peptide concentration. 
2) 200 µl of Triton solution were added into a sterile tube with 200 µl of red blood 
cell suspension as a positive control (100% haemolysis). 5 replicates were made for 
this. 
3) 200 µl sterile PBS was added into a sterile tube with 200 µl of red blood cell 
suspension as negative control (blank 0% haemolysis). 5 replicate were made for 
this. 
4) The tubes were incubated for 120 min at 37℃. 
5) After incubation, all tubes were centrifuged at 100 × g for 5 min. 200 µl of 
supernatant from each tube were transferred to a 96-well plate. 
6) The absorbance at 550 nm was measured using a Synergy HT plate reader (BioTek, 
USA). 
7) The percentage of haemolysis was calculated using the following formula and a 
graph was drawn. The haemolysis assay was repeated at least three times and the 




Haemolysis% = (A-AO) / (AX-AO) * 100% 
Where A represents the OD (λ550) of peptide/ erythrocyte mixture, AX the OD (λ550) 
































3.1 “Shotgun” cloning of novel peptide biosynthetic precursor-encoding 
cDNA  
Using the molecular cloning strategy as described in section 2.1, a cDNA encoding 
the biosynthetic precursor of a new peptide was consistently cloned from the skin 
secretion library. The nucleotide and translated open-reading frame amino acid 
sequence of this cDNA are shown in Figure 3.1. 
 
Figure 3.1 Nucleotide and translated open-reading frame amino acid sequence of 
biosynthetic precursor cDNA encoding the novel mature peptide. The putative signal 
peptide is single-underlined, the mature peptide is double-underlined, and the stop 





3.2 MALDI-TOF-MS of QUB1977 
The synthetic QUB1977 was analysed by MALDI-TOF mass spectrometry. The major 
peptide ion observed at m/z 1977.11, was consistent with the desired sequence（Figure 
3.2）. 
 









































3.3 Secondary structure prediction by HELI-QUEST 
The physiochemical properties and structure of QUB1977 were preliminarily 
predicted by the online tool HELI-QUEST. This peptide contained two positively 
charged residues (Lysines), a hydrophobic face and twelve nonpolar residues 
constituting almost two thirds of the residues. 
 









3.4 Antimicrobial assays 
The synthetic replicate of QUB1977 exhibited effective growth inhibition of the 
Gram-positive bacrerium, S.aureus (Figure 3.3.1), the Gram-negative bacterium, 
E.coli (Figure 3.3.2) and the yeast, C.albicans (Figure 3.3.3). MICs were 4, 32 and 4 
μM, respectively. Their corresponding MBCs were 8, 128 and 4 μM, respectively. 
 
Figure 3.4.1 MIC of QUB1977 against S. aureus (λ=550 nm) 
 




















3.5 Haemolysis activity 
The haemolysis assay showed that the concentration of the test peptide which induced 
50% haemolysis (HC50 value) was 23 μM (Figure 3.4). The assay was repeated 3 
times, each of 5 replicates.  
 


























Discussion and conclusion  
Amphibian skin has been considered as a “treasure store” of bioactive peptides on 
which numerous research groups have focused their attention. Some advanced 
technologies and methodologies like high throughput molecular techniques involving 
de novo peptide sequencing via tandem mass spectrometry, cDNA cloning, 
pharmacological screening, and surface plasmon resonance applied to peptide 
discovery, have led to fast structural data acquisition and the generation of peptide 
molecular libraries (de Azevedo Calderon, 2011). Based on the current plight of many 
of the amphibians worldwide, the method of extracting and identifying the novel 
peptide from the skin secretion used in this work is highly favorable. This high 
throughout method can identify the skin secretion components without sacrificing the 
specimens. 
 
Generally, the therapeutic potential of the host-defence peptides from frog skin 
secretions has not been fully realised since many peptides have multifunctional 
activities such as anti-cancer, anti-viral, immunomodulatory and as anti-diabetic 
agents (Conlon et al., 2014). Among all these peptides, antimicrobial peptides (AMPs) 
have attracted the most attention for their potential as agents against 
multidrug-resistant pathogens. AMPs that have been escalating as biological weapons 
in living organisms over millions of years, with no doubt, constitute part of the 
immune system of multicellular creatures. Since the dose of killing or inhibiting 
bacteria is not very large—normally at micromolar concentrations and AMPs do not 
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interact with specific receptors, it is rare for these to induce drug resistance. 
 
However, unless a long-acting, non-toxic analogue can be developed, the rapid 
clearance of the peptide in the circulatory system will keep preventing the possibility 
of systemic administration. Peptides used in the form of sprays or ointments for 
infection or damage of the skin can penetrate into the stratum corneum to kill the 
microorganisms. In this case, future therapeutic applications would tend to be 
administered topically like the treatment of diabetic foot ulcers, impetigo, and to 
promote wound healing. 
 
Sequence of the QUB1977 was compared with other known peptides by 
NCBI-BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The sequence of QUB1977 
was similar with Phylloseptin-2 and Phylloseptin-PT from Phyllomedusa tarsius with 
95% identities. Therefore, QUB1977 was considered as a member of phylloseptin 
family. 
 
Many studies have proven that phylloseptins show antimicrobial activity against 
Gram-negative bacteria: Acinetobacter calcoaceticus, Escherichia coli, and 
Pseudomonas aeruginosa (Leite et al., 2005; Resende et al., 2008); Gram-positive 
bacteria: Enterococcus faecalis, Klebsiella peneumoniae, Staphylococcus aureus, and 
Streptococcus agalactiae; Fungi: Candida albicans (Resende et al., 2008); and 
Protozoa: Leishmania amazonensis (promastigotes) (Ku c¨kelhaus et al., 2009), 
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Plasmodium falciparum (rings, trophozoites, and schizonts) (Ku c¨kelhaus et al., 2009), 
and Trypanosoma cruzi (trypomastigotes) (Leite et al., 2005). 
 
As can be seen here, this novel AMP of the phylloseptin family, from the skin 
secretion of Phyllomedusa camba, displayed broad-spectrum activity against the 
Gram-positive bacterium, Staphylococcus aureus, the Gram-negative bacterium, 
Escherichia coli and the yeast, Candida albicans, with MICs of 4, 32 and 4 μM, 
respectively. 
 
This observation was consistent with the finding from other phylloseptins that 
peptides from this family show a biased selectivity for prokaryotic over eukaryotic 
membrane targets. This is because prokaryotic cell membranes contain relatively 
more negatively charged phospholipids at the outer leaflet of the membrane bilayer 
(Zasloff, 2002). Thus, the appropriate application of the peptide studied here would be 
to reduce the numbers of Gram-positive and Gram-negative bacteria. 
 
The classical mechanism of AMPs involves cell membrane damage (Epand & Vogel, 
1999). The cationic compounds can interact with the negatively charged cell 
membrane or some AMPs destroy the cell membrane integrity by specifically 
interacting with the membrane compounds (Hancock, 2001). In addition to the 
physicochemical features of the lipids on the membranes of microbial targets, the 




This novel peptide, QUB1977, was analysed by an on-line tool named HELI-QUEST 
to obtain a preliminary idea of its secondary structure and some physicochemical 
characteristics. The peptide of 19 amino acid residues was typically cationic and 
contained an amphiphilic α–helix. The amphiphilic nature of this peptide was 
presumed to explain its biological activity through electrostatic interactions of the 
positively charged ions association with negatively charged cytoplasmic membranes 
subsequently leading to the disrupted cell membrane.  
 
The peptide QUB1977, shares the same structural characteristics with other 
phylloseptins, namely, a highly conserved sequence FLSLI[L]P in the N-terminal 
region and C-terminal amidation which has been shown to promote biological activity 
(Leite et al., 2005; Ali et al., 2001; Katayama et al., 2002). Nevertheless, the 
biological activity of phylloseptins may change radically if the sequence of model 
compounds has been slightly modified even though the total amino acid composition 
is constant (Wieprecht et al., 1997). This is because peptides which have slight 
modifications with an increased hydrophobic moment are considerably more active in 
interactions between lipid acyl chains and the hydrophobic helix core during the 
membrane-permeabilising process even though the number and positions of charged 
residues are constant. 
 
What is more, members of the phylloseptin family normally exhibit a weak effect on 
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red blood cells (Leite et al., 2005) and display some toxic effects on mammalian cells 
only at very high concentrations (Ku c¨kelhaus et al., 2009). For instance, 
phylloseptin-1 (PSN-1), from Phyllomedusa sauvagei skin secretion, had no 
haemolytic activity at the tested concentrations against S.aureus (Zhang, 2010). 
 
While in this assay, a significant haemolytic activity (EC50 of 23 μM) was 
demonstrated, it is concluded that the peptide here may become a lead compound for 
future drugs against Gram-positive bacteria and yeasts instead of against 
Gram-negative bacteria （MIC of E.coli: 32 μM）. 
 
Haemolysis is a common feature of many AMPs and is an unfavorable effect that 
hinders their use in systemic therapy. However, this problem can be solved by 
rationally designing structural analogues of major molecules, which is common in 
drug development. 
 
On the other hand, due to the ever-changing revisions of species taxonomy in anurans, 
some confusion may be caused. For example, some publications named the peptides 
according to their evolutionary origin or functional similarities while some chose to 
name the peptides by initial letters from the name of the species, all of these making 
the situation more complicated. Therefore, it is highly recommended that there should 
be a consistent nomenclatural system not only for AMPs but also for peptides which 
are active as anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents 
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(Conlon et al., 2014).  
 
Some existing nomenclatural systems can be referred to, such as the online reference 
from Frost (Frost, 2014) or a practical nomenclatural system proposed by Conlon 
(Conlon, 2008). Besides, the Basic Local Alignment Search Tool (BLAST) can help 
to compare similarity with existing peptides. 
 
Ultimately, AMPs are highly likely to be useful therapeutic tools because they are not 
only able to kill bacteria, but also viruses and fungi. In addition, their antimicrobial 
activity is exerted due to their multifunctional properties. This feature makes 
microbial resistance more difficult to develop. Today, our in-depth research will 
further develop the knowledge in this field and highlight the value of AMPs as 
potential therapeutic agents. 
 
Future work 
AMPs are promising as alternatives to antibiotics in the near future because of their 
properties of killing pathogenic microorganisms and they will absolutely have a 
positive effect on human life expectancy. It will soon become a reality that people 
manage the design and use of AMPs against various antibiotic-resistant bacterial 
pathogens. 
There are some methods that may help this peptide to become more effective in 




AMPs can work with traditional antibiotics. 
A variety of AMPs can work together as a cocktail agent. 
Make structural modification on AMPs. 
In conclusion, a thorough understanding of the correlation between the structure and 
function of AMPs will help rationally design cheaper and more effective analogues 
(Hwang & Vogel, 1998; Hyberts, 1992). Through some specific post-translational 
modifications including amidation, disulphide-bonding, L-to-D amino acid 
isomerisation, tyrosine-sulphation, proline-hydroxylation and amino terminal 
pyroglutamate formation and so on, new functions of AMPs may develop and 
cytotoxicity may be reduced. Therefore, further work needs to be done on the 
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